<DOC>
	<DOCNO>NCT00016068</DOCNO>
	<brief_summary>RATIONALE : Antivirals valganciclovir act virus may effective prevent cytomegalovirus . It yet know valganciclovir effective preventing cytomegalovirus . PURPOSE : This randomized phase III trial study valganciclovir see well work prevent cytomegalovirus patient undergone donor stem cell transplantation .</brief_summary>
	<brief_title>Valganciclovir Prevent Cytomegalovirus Infection Patients Following Donor Stem Cell Transplantation</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare cytomegalovirus ( CMV ) disease non-CMV invasive infection-free survival patient undergo allogeneic hematopoietic stem cell transplantation treat valganciclovir v placebo . - Compare incidence CMV disease patient treat drug . - Compare incidence severe invasive bacterial fungal infection overall survival patient treat drug . Secondary - Compare incidence CMV infection disease baseline day 270 640 allogeneic hematopoietic stem cell transplantation patient treat drug . - Compare incidence herpes simplex virus varicella-zoster virus infection baseline day 270 patient treated drug . - Determine safety valganciclovir patient . - Compare quality life patient treat drug . - Compare CMV-specific immune reconstitution patient treat drug . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord participate center , prior neutropenia ( yes v ) , presence refractory graft-versus-host disease require secondary therapy ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral valganciclovir daily . - Arm II : Patients receive oral placebo daily . Treatment begin around day 80-120 post-transplantation continue day 270 post-transplantation absence active infection unacceptable toxicity . Patients develop active cytomegalovirus ( CMV ) infection receive induction dos ganciclovir IV open-label oral valganciclovir 1 week follow open-label oral valganciclovir maintenance dose CMV longer detect . Quality life assess baseline day 180 270 post-transplantation . Patients follow day 400 , 520 , 640 post-transplantation . PROJECTED ACCRUAL : A total 184 patient ( 92 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Have undergone allogeneic peripheral blood stem cell , cord blood , marrow transplantation ( relate unrelated , Tcell deplete nonTcell deplete , CD34selected nonselected , myeloablative nonmyeloablative ) within past 80120 day Positive pretransplantation cytomegalovirus ( CMV ) serology recipient and/or donor Seropositive recipients one following : CMV infection day 80 , determine : pp65 antigenemia CMV DNA plasma Peripheral blood leukocyte ( PBL ) whole blood level detect polymerase chain reaction hybrid capture CMV pp67 mRNA CMV viremia blood culture Surveillance bronchoalveolar lavage ( culture cytology ) CMV disease 6 week prior enrollment Presence graftversushost disease ( GVHD ) enrollment Acute GVHD require treatment systemic corticosteroid dos great 0.5 mg/kg OR Chronic clinically extensive GVHD require treatment corticosteroid Continuous prophylaxis ganciclovir , foscarnet , cidofovir engraftment day 80 OR Seronegative recipient seropositive donor CMV infection day 80 No rise uncontrolled CMV load ( pp65 antigenemia level great 1/slide great 100 copy CMV DNA per mL plasma per million PBL allow ) No CMV disease within 6 week prior randomization No leukemic relapse Cytogenetic molecular relapse allow PATIENT CHARACTERISTICS : Age : 16 Performance status : Not specify Life expectancy : At least 2 week Hematopoietic : Absolute neutrophil count least 1,000/mm^3 least 1 week prior enrollment Hepatic : Not specify Renal : Creatinine great 2.5 mg/mL Other : No hypersensitivity ganciclovir valganciclovir No uncontrolled diarrhea severe gastrointestinal disease would preclude oral medication Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 90 day study participation HIV negative Proficient English PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : Not specify Endocrine therapy : See Disease Characteristics Radiotherapy : Not specify Surgery : Not specify Other : Prior ganciclovir , foscarnet , cidofovir , highdose acyclovir , valacyclovir prophylaxis preemptive therapy allow No concurrent prophylactic foscarnet , cidofovir , ganciclovir ( IV oral ) No concurrent prophylactic highdose acyclovir ( 800 mg twice daily ) , valacyclovir ( 500 mg twice daily ) , cidofovir ( 0.5 mg/kg per week ) , famciclovir ( 500 mg/day ) except limited treatment course high dos varicellazoster virus infection Concurrent lowdose ( â‰¤ 0.5 mg/kg per week ) cidofovir allow limited treatment course</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>infection</keyword>
</DOC>